JC: The PATCH trial. TXA in major trauma. St Emlyn’s
Critical Appraisal of the The PATCH trial of TXA Tranexamic Acid in major trauma patients. TXA saves lives, but functional outcomes vary. #FOAMed @stemlyns
Critical Appraisal of the The PATCH trial of TXA Tranexamic Acid in major trauma patients. TXA saves lives, but functional outcomes vary. #FOAMed @stemlyns
Tranexamic acid in trauma is a well-established standard of care in most mature trauma systems. The two major trials of TXA, CRASH 2 and 3 suggest a small but important …
Differential prescribing of TXA by gender. St Emlyn’s Read More »
Our regular podcast round up from February 2021. Iain and Simon highlight the key learning points from this month on the St Emlyn’s blog and podcast. Please remember to subscribe …
Over the years we have had more than a passing interest in tranexamic acid. In part because we have been involved in some of the research, recruiting to trials, or …
JC: The NoPAC trial. TXA does not work for epistaxis. St Emlyn’s Read More »
This post is co-published with our friends at REBEL EM. Background: It almost seems that when it comes to the use of the antifibrinolytic agent tranexamic acid (TXA) in trauma, …
Welcome to our audio round up of everything on the blog during September. It’s been a relatively quiet on the blog post this month, but we chat through not only …
Tranexamic Acid (TXA) is a mainstay of trauma management. CRASH 2 (2) demonstrated its effectiveness in bleeding patients and CRASH 3 (1,5) (in my opinion) showed that we should also …
JC: Can we give tranexamic acid (TXA) via the IM route? St Emlyn’s Read More »
Our post on the CRASH-3 trial, an RCT examining the use of TXA in head injury, was arguably our most controversial of 2019 (1). Our view was that the evidence …